Treatment of Edema Syndrome in Patients with Chronic Cor Pulmonale
66 patients with chronic cor pulmonale and edema syndrome received torasemide. Additionally, the main group (21 patients) received angiotensin II receptor antagonist - irbesartan. Hemodynamic parameters, parameters of ventilation and renin-angiotensin-aldosterone system as well as dynamics of cyclic nucleotides and endothelin-1 were investigated. More pronounced positive clinical and laboratory changes resulting in edema syndrome and recovery of myocardial function were observed in the main group of patients who received torasemide and irbesartan compared to the comparison group.
Global strategy for diagnosis, management, and prevention of COPD. Belevskoy AS, editor. Rossiyskoe respiratornoe obshchestvo. Moscow. 2012;80.
Denysova SV, Yaroshenko IO, Pogorelov VM, et al. Chronic pulmonary heart disease and treatment of edema syndrome. Medytsyna transportu Ukraiiny. 2009;2(30):43-46.
Irkin OI. The use of loop diuretics: can torasemide be used as a first-line drug? Zdorovia Ukraiiny. 2013;5(30):61.
Pogorelov VN, Brek VV, Prokhorenko VL, et al. Some aspects of treating patients with chronic pulmonary heart disease complicated by congestive heart failure. Eksperymentalna i klinichna medytsyna. 2014;1(62):85-90.
Prykhodko VYu. Diuretics in therapeutic practice: the place of torasemide. Sertseva nedostatnist. 2011;2:133-137.
Radchenko HD, Kushnyr SM, Sirenko YuM, et al. The experience of using torasemide in patients with arterial hypertension and reduced renal function. Arterialnaya gipertenziya. 2010;5(13):13-19.
Mostovyi YuM. Modern classifications and standards for treatment of the diseases of internal organs. Emergencies in therapy. Mostovyi YuM, editor. Tsentr DKZ. Kyiv. 2014;674.
Baguet JP, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am. J. Cardiovasc Drugs. 2005;5(2):131-140.
White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. AmJ. Hypertens. 2004;17(4):347-353.
Wilkens H. Pulmonary hypertension. Pathophysiology and current concepts of medication therapy. Anaesthesist. 2004;53(8):734-40.
Copyright (c) 2015 V. M. Pogorelov, V. V. Brek, O. S. Kovalenko, O. V. Zaytseva
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).